Alector Inc. announced that management will host a virtual research and development event to discuss its wholly owned Alector Brain Carrier (ABC) blood-brain barrier platform and the company's ABC-enabled pipeline.

The webinar, titled "Alector Pipeline Webinar: Advancing Next Generation Medicines for Neurodegeneration," is scheduled for Tuesday, October 13, 2026, at 8:00 am PT. The agenda features progress updates on lead anti-amyloid beta antibody AL137, tau siRNA program AL164, and alpha-synuclein siRNA program AL062.

Event details and access

A live question and answer session will follow the formal presentation. Investors can register for the live webcast or visit the "Events and Presentations" section of the company website. An archived replay will be available for approximately 90 days following the presentation.

Pipeline highlights

The event will focus on three key areas of the company's portfolio:

• AL137: A next-generation anti-Aβ antibody targeting the pyroglutamate Aβ epitope. It utilizes the unique TfR-binding domain of the ABC platform, designed to limit immune-cell recruitment to reticulocytes while preserving full recruitment to Aβ plaques. This approach aims to reduce hematologic risk without compromising plaque clearance. AL137 is designed for enhanced brain exposure, reduced amyloid-related imaging abnormalities (ARIA) risk, and monthly subcutaneous dosing.
• AL164, AL062 and ADP065: These are ABC-enabled siRNA programs targeting tau, α-synuclein, and NLRP3, respectively. The company will present preclinical data demonstrating potent target reduction across multiple brain regions. These brain-penetrant nucleic acid therapies are designed to address intracellular drivers of Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. Each program is designed for once-quarterly subcutaneous dosing.

About the technology

The Alector Brain Carrier (ABC) is a proprietary blood-brain barrier platform applied to the company's preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration, and enable efficacy at lower doses. The company states this approach seeks to improve patient outcomes while reducing costs.

Alector is headquartered in South San Francisco, California, and focuses on developing therapies to counteract the progression of neurodegenerative diseases by leveraging genetics, immunology, and neuroscience.

Alector Inc has entered an exclusive global licensing agreement with Genentech, a member of the Roche Group, granting worldwide rights to develop and commercialize its AL050 program. The deal provides Alector with $100 million upfront and potential milestone payments of up to $1.17 billion, plus tiered royalties on net sales.

This partnership targets neurodegeneration driven by glucocerebrosidase (GCase) deficiency in Parkinson’s Disease. AL050 is a brain-penetrant engineered enzyme replacement therapy (ERT) designed to address GCase deficiency. This deficiency is a key driver of neurodegeneration in Parkinson’s patients, particularly pronounced in carriers of GBA1 mutations. The therapy combines Alector-engineered GCase, optimized for higher enzymatic activity and longer half-life, with the company’s ABC technology, which facilitates transport across the blood-brain barrier.

Deal Structure and Financial Impact

Genentech takes responsibility for development, regulatory activities, manufacturing and commercialization worldwide. The financial terms significantly bolster Alector's balance sheet. CEO Arnon Rosenthal stated that the partnership "extends our cash runway into 2029," providing resources to advance Alector’s brain-enabled anti-amyloid antibody program as well as tau and alpha-synuclein siRNA programs.

Mechanism of Action

Once delivered into the brain, the engineered enzyme aims to break down specific lipids that accumulate in neurons due to GCase deficiency. These lipids, including glucosylsphingosine and glucosylceramide, contribute to cellular dysfunction and disease progression.

Strategic Implications

The agreement grants Genentech exclusive rights to the AL050 program globally. This move leverages Genentech’s commercial infrastructure while allowing Alector to focus on its core biotechnology platform. Crucially, Alector retains ownership of the ABC platform, leaving the company free to apply the brain-delivery technology across its wholly owned pipeline. The collaboration highlights the industry’s continued interest in addressing neurodegenerative conditions through advanced delivery mechanisms.